Hansoh Pharmaceutical Group Company Limited (HNSPF)

Market Cap	32.31B
Revenue (ttm)	1.84B
Net Income (ttm)	667.42M
Shares Out	n/a
EPS (ttm)	0.11
PE Ratio	48.41
Forward PE	43.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,000
Average Volume	1,626
Open	4.900
Previous Close	4.850
Day's Range	4.900 - 4.900
52-Week Range	1.950 - 5.200
Beta	0.59
RSI	63.53
Earnings Date	Mar 19, 2026

About HNSPF

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 8,989
• Stock Exchange: OTCMKTS
• Ticker Symbol: HNSPF

Financial Performance

In 2024, HNSPF's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY